1st Quarter - Report

HUMANA, INC. for HUMANA INC

Firm
Client
Income
—
Expenses
$2,040,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

TRICARE Policy Issues including Telehealth and Value-Based Care NDAA Implementation Policy Issues Veterans Healthcare and Policy Issues

LobbyistCovered position, as disclosed
VERONICA JACKSON —
JEFFREY LUNGREN —
RACHEL MAGNUSON —
ALEXANDER WARE —

Contacted: Veterans Affairs, Dept of (VA); Defense, Dept of (DOD); SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Tax Reform Implementation Issues

LobbyistCovered position, as disclosed
VERONICA JACKSON —
JEFFREY LUNGREN —
RACHEL MAGNUSON —
ALEXANDER WARE —

Contacted: White House Office; HOUSE OF REPRESENTATIVES; SENATE; Treasury, Dept of

Pharmacy PHA

Prescription drug pricing Pharmacy Benefit Managers (PBM) and Pharmacy Policy and Reimbursement Issues Prescription Drug Rebate Issues

LobbyistCovered position, as disclosed
VERONICA JACKSON —
JEFFREY LUNGREN —
RACHEL MAGNUSON —
ALEXANDER WARE —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; White House Office; Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB)

Health Issues HCR

Implementation of Inflation Reduction Act of 2022 Public Law No. 117-169 CMS-0057-P Interoperability and Prior Authorization Proposed Rule Clinical Policy Issues Including Workforce and Mental Health Employer Group Coverage Policy Issues

LobbyistCovered position, as disclosed
VERONICA JACKSON —
JEFFREY LUNGREN —
RACHEL MAGNUSON —
ALEXANDER WARE —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); SENATE; White House Office; Food & Drug Administration (FDA)

Medicare/Medicaid MMM

Medicare Advantage (MA) Policy and Reimbursement Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies (CMS- 2023-0010) CMS-4201-P CY 2024 Medicare Advantage (MA) & Part D Policy and Technical Changes Proposed Rule Announcement of Calendar Year (CY) 2024 Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies Medicare Part D Issues Medicaid Policy Issues Including Redeterminations and Dual Eligibles Pharmacy Benefit Managers (PBM) and Pharmacy Policy and Reimbursement Issues Home Health and Hospice Policy Issues Prescription Drug Rebate Issues Implementation of Inflation Reduction Act of 2022 Public Law No. 117-169 S. 3018/H.R. 3173, Improving Seniors Timely Access to Care Act (117th Congress) CMS-0057-P Interoperability and Prior Authorization Proposed Rule CMS Guidance on Direct Negotiation (Official Title: Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments) CMS-4185-F2 Medicare Advantage Risk Adjustment Data Validation Final Rule CMS-1787-P FY 2024 Hospice Payment Rate Update Proposed Rule Primary Care and Value-Based Care Policy and Reimbursement Clinical Policy Issues Including Workforce and Mental Health

LobbyistCovered position, as disclosed
VERONICA JACKSON —
JEFFREY LUNGREN —
RACHEL MAGNUSON —
ALEXANDER WARE —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; White House Office; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB)

Bills named: S. 3018 (118th), H.R. 3173 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.